Ironwood Capital Management LLC
07/17/2018 | Press release | Archived content
Ironwood Capital Connecticut Portfolio Company IsoPlexis: Response noted in non-Hodgkin patients
Back to all news
07/17/2018 | In the News
Ironwood Capital Connecticut Portfolio Company IsoPlexis: Response noted in non-Hodgkin patients
Reprinted from BioCT, June 22, 2018 IsoPlexis has announced the publication of clinical data demonstrating a significant association between the functionality of anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis' Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma.
"We were excited to collaborate on this groundbreaking research," said IsoPlexis Chief Executive Officer Sean Mackay. "Using our single-cell predictive profiling platform, leading oncology and immunotherapy researchers and clinicians were able to collect this data, which demonstrates a potential to be able to apply the right therapies to the right patients and continue to personalize cancer immunotherapies, as these therapies continue to provide significant benefits to patients worldwide."
Previous Article Next Article
Ironwood Capital Management LLC published this content on July 17, 2018, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 15, 2026 at 06:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]